FDA Asked To Withdraw Approval Of Test Evaluating Opioid Addiction Risk
Executive Summary
Dozens of researchers signed a letter condemning the AvertD test from SOLVD, which looks for genes that may contribute to a propensity toward opioid addiction. But the FDA and the manufacturer both say the test is effective.